investigators were also able to demonstrate the long-term effects of pravastatin on
reducing CRP. At baseline, CRP levels were identical in both the placebo- and
pravastatin-treated groups. However, at the end of 5 years, CRP levels were markedly
reduced with pravastatin. Similar data have now been shown for statins at as early as 1
year and perhaps as early as 6 to 8 weeks.
Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E, for the Cholesterol and Recurrent
Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of
C-reactive protein. Circulation 1999;100:230-235.